CM Management LLC Acquires New Position in Compass Therapeutics, Inc. $CMPX

CM Management LLC acquired a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) in the 3rd quarter, HoldingsChannel reports. The firm acquired 150,000 shares of the company’s stock, valued at approximately $525,000.

A number of other institutional investors also recently bought and sold shares of CMPX. Creative Planning purchased a new stake in shares of Compass Therapeutics in the 2nd quarter valued at approximately $30,000. Strs Ohio acquired a new stake in shares of Compass Therapeutics during the 1st quarter worth approximately $34,000. Apollon Wealth Management LLC purchased a new stake in shares of Compass Therapeutics during the 3rd quarter valued at approximately $35,000. Victory Capital Management Inc. raised its position in shares of Compass Therapeutics by 20.6% during the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock valued at $44,000 after buying an additional 2,164 shares during the period. Finally, Welch & Forbes LLC acquired a new position in Compass Therapeutics in the third quarter valued at approximately $52,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Compass Therapeutics

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Phase 2/3 COMPANION‑002 tovecimig trial hit the prespecified event threshold (≈80% OS events), so prespecified PFS and OS analyses are expected to be reported in April — a near-term binary clinical readout that could materially move the stock. Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Management opened expansion cohorts for CTX‑8371 in TNBC and NSCLC and will add a Hodgkin lymphoma cohort after an additional response — further clinical activity and potential signals that can drive upside. Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Q4 results: CMPX reported ($0.09) EPS, beating the consensus ($0.10) loss by $0.01 — a small beat that can be supportive for sentiment. View Press Release
• Neutral Sentiment: HC Wainwright published 2026 quarterly EPS forecasts (Q1: ‑$0.09, Q2: ‑$0.10, Q3: ‑$0.10, Q4: ‑$0.11) and a full‑year loss estimate of ‑$0.36 — these reinforce expectations for continued operating losses but are broadly in line with prior guidance. MarketBeat CMPX
• Negative Sentiment: Reports indicate a “large increase” in short interest in early March, but the published figures show 0 shares and NaN changes (data appears inconsistent). If short interest is actually rising, that would be a bearish signal; the current reporting ambiguity may add volatility. MarketBeat CMPX

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on CMPX shares. Jefferies Financial Group reiterated a “buy” rating and issued a $9.00 price objective on shares of Compass Therapeutics in a research report on Thursday. D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a research note on Tuesday, January 6th. Citizens Jmp set a $10.00 price target on Compass Therapeutics in a report on Wednesday, December 3rd. William Blair reissued an “outperform” rating on shares of Compass Therapeutics in a research report on Thursday. Finally, Raymond James Financial restated an “outperform” rating on shares of Compass Therapeutics in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Compass Therapeutics Stock Performance

Compass Therapeutics stock opened at $5.51 on Friday. The company has a market capitalization of $980.01 million, a PE ratio of -12.81 and a beta of 1.48. Compass Therapeutics, Inc. has a fifty-two week low of $1.33 and a fifty-two week high of $6.88. The firm has a 50 day moving average price of $5.90 and a 200 day moving average price of $4.81.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. As a group, equities research analysts forecast that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.